- Trial phase
- Phase 3
- Time to market
- Unknown; Phase 3 trials began enrolling in 2026. If successful, potential regulatory filings would be at least 2-4 years away (2028-2030).
- Why 4/10
- No hard dated catalyst (PDUFA, pivotal readout) is scheduled in the next ~12 months, the five Phase 3 trials began enrolling in 2026 and pivotal readouts are likely 2-3+ years away. GSK is a large-cap diversified pharma, so this single early-stage asset drives a small fraction of the stock's value.
GSK just presented updated BEHOLD-1 Phase 1b data at ESMO 2026 (Oct 23-27) showing a 62% confirmed ORR at the 5.8 mg/kg Phase 3 dose in platinum-resistant ovarian cancer. The next catalysts are Phase 3 interim/final readouts from the five pivotal trials (BEHOLD-Ovarian01, BEHOLD-Endometrial01, etc.) that began enrolling in 2026, those readouts are likely 2-3+ years away. For a large-cap pharma like GSK, this is one of many pipeline assets and not a near-term binary event.
Price Chart
Executive Summary
Mocertatug rezetecan (Mo-Rez, GSK5733584, HS-20089) is an investigational B7-H4-targeted antibody-drug conjugate (ADC) being developed by GSK plc for gynecologic cancers. It was licensed from Hansoh Pharma in October 2023 for $85M upfront. Updated Phase 1b BEHOLD-1 data presented at ESMO 2026 (this week) showed a 62% confirmed objective response rate at the selected Phase 3 dose of 5.8 mg/kg in platinum-resistant ovarian cancer, with median duration of response of 12.2 months and median PFS of 11.1 months. GSK has initiated five global Phase 3 pivotal trials in 2026. The drug also received Breakthrough Therapy Designation from China's NMPA in May 2025. For a large-cap pharma like GSK, this is a promising but early-stage pipeline asset with no near-term binary catalyst.
How It Works
An antibody-drug conjugate (ADC), a precision cancer therapy that works like a guided missile. One part of the drug (the antibody) locks onto a protein called B7-H4 found on the surface of ovarian and endometrial cancer cells. Once attached, the cancer cell pulls the drug inside, where a chemotherapy payload (a topoisomerase 1 inhibitor called rezetecan) is released to kill the cell. The design aims to deliver the chemotherapy directly to tumors while sparing healthy tissue.
Trial Status
Phase 1b BEHOLD-1 trial completed enrollment and reported updated data at ESMO 2026 (October 2026) with 62% ORR in PROC and 67% in endometrial cancer. Five global Phase 3 pivotal trials (BEHOLD-Ovarian01, BEHOLD-Endometrial01, and others) began enrolling patients in 2026. A Phase 1/2 BEHOLD-2 combination study is also ongoing.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 interim/final data readouts from BEHOLD-Ovarian01 (NCT07286266) and BEHOLD-Endometrial01 (NCT07286331), likely 2-3+ years out
- Potential regulatory submissions in China following NMPA Breakthrough Therapy Designation (timeline unclear)
- Additional data from BEHOLD-2 combination study
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GSK plc 6-K GSK ·Originating report